Group 1 - The core point of the article is that Haier Biomedical (688139.SH) has completed its share repurchase program, acquiring a total of 3,087,899 shares, which represents 0.9757% of the company's total share capital [1] - The highest repurchase price was 34.69 CNY per share, while the lowest was 29.86 CNY per share, with an average repurchase price of 32.39 CNY per share [1] - The total amount spent on the repurchase reached 100.0042 million CNY (excluding transaction fees), which is within the limits set by the company's repurchase plan [1]

Core Viewpoint - Haier Bio announced a share repurchase plan, with a total expected repurchase amount of 100 to 200 million yuan, aimed at enhancing shareholder value and supporting employee stock ownership plans [1] Group 1: Share Repurchase Details - The repurchase plan was approved on January 13, 2025, with a repurchase period from January 14, 2025, to January 13, 2026 [1] - As of January 13, 2026, the company completed the repurchase of 3.0879 million shares, accounting for 0.9757% of the total share capital, with a total transaction amount of 100 million 42 thousand yuan [1] - The repurchase price ranged from 29.86 to 34.69 yuan per share [1] Group 2: Shareholder Actions - From January 14 to April 10, 2025, the company's actual controller and concerted party, Haichuangzhi, increased its holdings by 3.8535 million shares, bringing the cumulative shareholding ratio to 2.74% [1]

Group 1 - The core viewpoint of the news is that Haier Biomedical has shown a positive stock performance with a 5.48% increase year-to-date and a market capitalization of 10.609 billion yuan as of January 12 [1] - As of December 31, the number of shareholders for Haier Biomedical is 13,100, a slight decrease of 0.10% from the previous period, while the average circulating shares per person increased by 0.10% to 24,261 shares [2] - The company reported a revenue of 1.761 billion yuan for the period from January to September 2025, reflecting a year-on-year decrease of 1.17%, and a net profit attributable to shareholders of 198 million yuan, down 35.83% year-on-year [2] Group 2 - Haier Biomedical has distributed a total of 788 million yuan in dividends since its A-share listing, with 452 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.7302 million shares, an increase of 928,500 shares compared to the previous period, while Huabao Zhongzheng Medical ETF holds 5.4557 million shares, a decrease of 776,900 shares [3]

Core Viewpoint - The company has approved a change in the purpose of repurchased shares, shifting from employee stock ownership plans to cancellation and reduction of registered capital [1]. Group 1: Share Repurchase and Capital Reduction - The company’s board and shareholders have agreed to adjust the use of 1,459,586 repurchased shares from "for employee stock ownership plans or equity incentives" to "for cancellation and corresponding reduction of registered capital" [1]. - The company has completed the necessary registration changes and obtained a new business license reflecting the updated registered capital of 316,492,922 yuan [1]. Group 2: Company Information - The company is named Qingdao Haier Biomedical Co., Ltd., with a unified social credit code of 91370211780374731M, established on October 28, 2005 [1]. - The company operates in various sectors including medical device technology research and development, production, sales, and after-sales services, as well as other related fields [1].

证券代码：688139 证券简称：海尔生物 公告编号：2026-003 青岛海尔生物医疗股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 青岛海尔生物医疗股份有限公司（以下简称"公司"）于2025年10月30日、2025年11月17日分别召开了第 三届董事会第八次会议和2025年第一次临时股东大会，分别审议通过了《关于变更部分回购股份用途并 注销暨减少注册资本的议案》，同意公司将存放于回购专用账户中的1,459,586股已回购股份的用途进行 调整，由"用于员工持股计划或股权激励"调整为"用于注销并相应减少注册资本"，同时按照相关规定办 理注销手续，具体内容详见公司分别于2025年10月31日和2025年11月18日在上海证券交易所网站 （www.sse.com.cn）披露的《青岛海尔生物医疗股份有限公司关于变更部分回购股份用途并注销暨减少 注册资本的公告》（公告编号：2025-049）和《青岛海尔生物医疗股份有限公司2025年第一次临时股东 大会决议公告》（公告编号：2 ...

Core Viewpoint - The company emphasizes its commitment to investor returns through various methods, including cash dividends, investor relations management, information disclosure, and share buybacks, while focusing on enhancing operational efficiency and profitability through innovation and strategic investments [1] Group 1: Investor Returns - The company has implemented continuous dividends for six years since its listing, with a total dividend payout of 788 million yuan, and the dividend ratio for the 2024 fiscal year has been increased to 40.31% [1] - The actual controller's concerted actors have increased their holdings in the company three times, with a total investment of approximately 384 million yuan [1] - The company has launched three rounds of share buyback plans, with a cumulative buyback amount of about 249 million yuan as of December 31, 2025 [1] Group 2: Share Buyback and Cancellation - To fulfill commitments regarding the buyback plan and enhance investor returns, the company canceled 1,459,586 shares from its buyback on January 6, 2026 [1] Group 3: Business Strategy and Growth - The company focuses on enhancing value creation capabilities through technological innovation, scenario upgrades, and globalization to improve operational efficiency and profitability [1] - It aims to accelerate investment and acquisition processes to strengthen existing industries and expand business boundaries, thereby reshaping its industrial development pattern and enhancing core competitiveness and investment value [1]

证券日报网讯 1月9日，海尔生物在互动平台回答投资者提问时表示，近年来受到复杂多变的全球和行 业形势等因素影响，公司业绩有所波动。今年前三季度，公司展现出较强的发展韧性，业绩于第二季度 触底后，在第三季度实现反弹，新产业占公司主营业务收入的比重已提升至48%；海外市场表现尤其亮 眼，今年前三季度收入增幅达20%、占公司主营业务收入的比重为36%，而过去六年来公司海外业务复 合增长率为25%，海外市场竞争力为公司业绩持续复苏提供了重要支撑。此外，公司持续推进"AI+"与 四大产业的深度融合，为公司市场份额提升和用户价值创造提供重要支撑，数智自动化样本方案前三季 度实现了翻番增长。未来，公司将继续坚持技术创新、场景升级和全球化发展，并加强与投资者的交 流。 （文章来源：证券日报） ...

证券日报网讯 1月9日，海尔生物发布公告称，公司已完成注册资本工商变更登记手续，并取得了青岛 市行政审批服务局换发的《营业执照》。 （文章来源：证券日报） ...

Core Viewpoint - Haier Biomedical has outlined its four major industry layouts, focusing on providing comprehensive biological safety solutions and integrated management systems across various healthcare and research sectors [2] Group 1: Industry Layouts - The low-temperature storage industry targets biological objects such as samples, pharmaceuticals, vaccines, and blood, offering solutions that cover a temperature range from -196°C to 8°C [2] - The laboratory solutions industry serves users in research, pharmaceuticals, and testing, providing comprehensive solutions that include general instruments, analytical instruments, consumables, and software [2] - The blood technology industry focuses on whole blood and component blood collection and preparation, offering intelligent solutions for blood stations and plasma stations, including collection equipment, consumables, and pharmaceuticals [2] - The smart medication industry addresses the full-process automated management needs of hospital pharmacies, inpatient pharmacies, infusion centers, and fever clinics, providing solutions for drug "transfer-distribution-use" [2]

Core Viewpoint - The company emphasizes that technological self-reliance is driving the industry towards domestic production, which further expands its development space and enhances market competitiveness across its four major industries [1] Market Position and Performance - The company's market share in the low-temperature storage industry continues to increase, with a projected market share of over 50% in plasma collection solutions by mid-2025, based on public and third-party bidding data [1] - The company ranks among the top three in the automated medication market and continues to break through in the domestic market for scientific instruments, with its total organic carbon analyzers and UV spectrophotometers being the top two domestic brands [1] - The centrifuge series has entered the top ten in market share among industry brands, while the biological safety cabinet has risen to the number one position nationwide, and the cultivation series maintains the highest market share among domestic brands [1] International Market Presence - Preliminary market research indicates that the company's three major low-temperature product lines hold the leading market share in 25 overseas countries [1]